Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 31, 2018 - Issue 3
76
Views
8
CrossRef citations to date
0
Altmetric
Case Studies

Flecainide toxicity in renal failure

, MBBS, , DO, , MBBS & , MD
Pages 328-330 | Received 29 Jan 2018, Accepted 05 Apr 2018, Published online: 09 May 2018

  • Vaughan Williams EM. The experimental basis for the choice of an anti-arrhythmic drug. Adv Cardiol. 1970;4:275–289. doi:10.1159/000387625. PMID:4395423.
  • January CT, Wann LS, Alpert JS, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1–e76. doi:10.1016/j.jacc.2014.03.022. PMID:24685669.
  • Tambocor (flecainide) package insert. https://www.iodine.com/drug/tambocor/fda-package-insert. Accessed March 30, 2018.
  • Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781–788. doi:10.1056/NEJM199103213241201. PMID:1900101.
  • Williams AJ, McQuinn RL, Walls J. Pharmacokinetics of flecainide acetate in patients with severe renal impairment. Clin Pharmacol Ther. 1988;43:449–455. doi:10.1038/clpt.1988.57. PMID:3128417.
  • Roden DM, Woosley RL. Drug therapy. Flecainide. N Engl J Med. 1986;315:36–41. doi:10.1056/NEJM198607033150106. PMID:3520324.
  • Conard GJ, Ober RE. Metabolism of flecainide. Am J Cardiol. 1984;53:41B–51B. doi:10.1016/0002-9149(84)90501-0. PMID:6364769.
  • Aliot E, Capucci A, Crijns HJ, Goette A, Tamargo J. Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace. 2011;13:161–173. doi:10.1093/europace/euq382. PMID:21138930.
  • Tamargo J, Le Heuzey JY, Mabo P. Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. Eur J Clin Pharmacol. 2015;71:549–567. doi:10.1007/s00228-015-1832-0. PMID:25870032.
  • Kerr GW, McGuffie AC, Wilkie S. Tricyclic antidepressant overdose: a review. Emerg Med J. 2001;18:236–241. doi:10.1136/emj.18.4.236. PMID:11435353.
  • Winkelmann BR, Leinberger H. Life-threatening flecainide toxicity. A pharmacodynamic approach. Ann Intern Med. 1987;106:807–814. doi:10.7326/0003-4819-106-6-807. PMID:3107447.
  • Liebelt EL, Francis PD, Woolf AD. ECG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity. Ann Emerg Med. 1995;26:195–201. doi:10.1016/S0196-0644(95)70151-6. PMID:7618783.
  • Williamson K, Mattu A, Plautz CU, Binder A, Brady WJ. Electrocardiographic applications of lead aVR. Am J Emerg Med. 2006;24:864–874. doi:10.1016/j.ajem.2006.05.013. PMID:17098112.
  • Goldman MJ, Mowry JB, Kirk MA. Sodium bicarbonate to correct widened QRS in a case of flecainide overdose. J Emerg Med. 1997;15:183–186. doi:10.1016/S0736-4679(96)00345-9. PMID:9144059.
  • Hoffman JR, McElroy CR. Bicarbonate therapy for dysrhythmia and hypotension in tricyclic antidepressant overdose. West J Med. 1981;134:60–64. PMID:6259839.
  • Bou-Abboud E, Nattel S. Relative role of alkalosis and sodium ions in reversal of class I antiarrhythmic drug induced sodium channel blockade by sodium bicarbonate. Circulation. 1996;94:1954–1961. doi:10.1161/01.CIR.94.8.1954. PMID:8873674.
  • Ellsworth H, Stellpflug SJ, Cole JB, Dolan JA, Harris CR. A life-threatening flecainide overdose treated with intravenous fat emulsion. Pacing Clin Electrophysiol. 2013;36:e87–e89. doi:10.1111/j.1540-8159.2012.03485.x. PMID:22882363.
  • Rothschild L, Bern S, Oswald S, Weinberg G. Intravenous lipid emulsion in clinical toxicology. Scand J Trauma Resusc Emerg Med. 2010;18:51. doi:10.1186/1757-7241-18-51. PMID:20923546.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.